Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood test, Cellulitis, Magnetic resonance imaging, Mammogram, Sepsis
Clinical narrative: cellulitis; Infection sepsis; This is a spontaneous report received from a Consumer or other non HCP.  A 73-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 18May2023 as dose 6 (booster), single (Lot number: GJ6796) at the age of 73 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Breast cancer (Lumpectomy radiation)", start date: 12Jan2018 (ongoing); "Breast cancer (Lumpectomy radiation)", start date: 2018 (not ongoing); "breast cancer (lumpectomy, radiation)", start date: 2018 (not ongoing); "torn meniscus (both knees)" (ongoing), notes: late 2003 (R), Feb 2015 (L), Arthroplasty rt knee; "Arthroplasty rt knee" (not ongoing); "Severe Spinal Stenosis", start date: 2016 (ongoing); "Broken arm (right)", start date: Jan1960, stop date: 1960, notes: Surgery, no plates or screws; "Broken arm surgery" (not ongoing); "Arthritis" (ongoing); "Blood pressure" (ongoing); "obesity" (unspecified if ongoing); "lymphedema (left arm after radiation) / lymphedema (right and left legs)" (unspecified if ongoing). Concomitant medication(s) included: DICLOFENAC taken for arthritis, start date: 27Feb2004 (ongoing); KIRKLAND SIGNATURE TRIPLE ACTION JOINT HEALTH, start date: 27Feb2004; DILTIAZEM taken for blood pressure abnormal, start date: 10Dec2008 (ongoing); NORDIC NATURALS ULTIMATE OMEGA, start date: 16Feb2018; ANASTROZOLE taken for breast cancer female, start date: Aug2018 (ongoing); NATURE'S BOUNTY CALCIUM WITH VITAMIN D3, start date: 14Mar2023. Past drug history included: Lisinopril, reaction(s): "Known allergies: lisinopril". Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Batch/lot number: EN6202, Anatomical Location: Right arm), administration date: 06Mar2021, when the patient was 71-year-old, for Covid-19 immunization; BNT162b2 (DOSE 2, SINGLE, Batch/lot number: EW0150, Anatomical Location: Right arm), administration date: 03Apr2021, when the patient was 71-year-old, for COVID-19 immunisation; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Batch/lot number: FF8839, Anatomical Location: Right arm), administration date: 06Oct2021, when the patient was 71-year-old, for COVID-19 immunisation; BNT162b2 (DOSE 4 (BOOSTER), SINGLE, Batch/lot number: FJ4991, Anatomical Location: Right arm), administration date: 21Apr2022, when the patient was 72-year-old, for COVID-19 immunisation; BNT162b2, BNT162b2 omi ba.4-5 (DOSE 5 (BOOSTER), SINGLE, Batch/lot number: GJ3275, Anatomical Location: Right arm), administration date: 01Nov2022, when the patient was 72-year-old, for COVID-19 immunisation. The following information was reported: SEPSIS (medically significant) with onset 12Jun2023, outcome "unknown", described as "Infection sepsis"; CELLULITIS (medically significant) with onset 12Jun2023 at 23:00, outcome "unknown". The patient underwent the following laboratory tests and procedures: Blood test: (unspecified date) OK; (12Jun2023) Infection Sepsis, Cellulitis; Magnetic resonance imaging: (Nov2023) Spinal stenosis; Mammogram: (Feb2023) OK; X-ray: (Nov2023) Spinal stenosis. Therapeutic measures were taken as a result of cellulitis, sepsis which included antibiotics.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400004455 same reporter/patient,different dose/AE;